-
Neuralstem ALS Trial Data Presented at the American Association of Neurological Surgeons Annual Meeting
Tuesday, April 30, 2013
Method of intraspinal cell delivery found to be safe, well-tolerated, and promising for other spinal cord conditionsROCKVILLE, Md., April 29, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that final data on the intraspinal delivery method employed in its NSI-566 Phase I trial to
-
Batavia Bioservices and UvA Holding Announce STEP™ Technology Exclusive License
Monday, April 29, 2013
Leiden, the Netherlands - Batavia Bioservices BV and UvA Holding BV announced today that they have successfully concluded an agreement granting Batavia Bioservices the exclusive rights to STEP™ technology developed by scientists at CellaGenics BV, an UvA Holding BV
-
Monoclonal Antibody With Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
Monday, April 29, 2013
MONROVIA, Calif. - Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for
-
ImmuneWorks' Phase 1 Clinical Trial Results Showcased at Needham Healthcare Conference
Friday, April 26, 2013
INDIANAPOLIS – ImmuneWorks, Inc., a biotechnology company developing novel therapeutics for patients with serious lung diseases, will present at the 12th Annual Needham Healthcare Conference, May 1 at 11:00 a.m., in Chicago, Illinois. President and CEO Wade A. Lange will present on behalf of
-
Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients With Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes
Friday, April 26, 2013
BOUDRY, Switzerland - Celgene International Sàrl today announced the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for REVLIMID® for the treatment of patients with transfusion-dependent anemia due to low or intermediate-1
-
Manufacture of BNC101 Commences at Lonza
Friday, April 26, 2013
Bionomics Limited announced that it has initiated manufacturing activities for BNC101, its lead anti-cancer stem cell candidate following completion of key preclinical studiesDr Deborah Rathjen, Bionomics CEO & Managing Director commented, "The start of manufacturing activities for BNC101 signals
-
Novel Screening Tests for Liver Cancer
Friday, April 26, 2013
Amsterdam, The Netherlands, Friday 26 April 2013: New data from two clinical trials presented today at the International Liver Congress™ 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine testsHCC i
-
Radioactive Bacteria Targets Metastatic Pancreatic Cancer
Thursday, April 25, 2013
BRONX, N.Y. - Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them. The experimental treatment dramatically decreased the number of "
-
Launch of the Avert-AF Scientific Initiative to Develop a Drug Treatment for the Prevention of Atrial Fibrillation
Thursday, April 25, 2013
ANN ARBOR, Mich. - Leading cardiovascular scientists today announced the launch of avert-AF, a new initiative aimed at developing drug treatments for the prevention of the more advanced forms of atrial fibrillationAtrial fibrillation (AF or A-fib) is the most common cardiac arrhythmia (irr
-
ArGEN-X Advances ARGX-113 Into Preclinical Development for Autoimmune Disorders
Thursday, April 25, 2013
BREDA, The Netherlands and GHENT, Belgium - First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodiesarGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human m